Mean SBP was reduced from baseline toweek52inthedapagliflozingroup(−4.10mmHg)butnotin the glipizide group (0.61mmHg). During the extension periods, the reduction in SBP was maintained in the dapagliflozin group, but patients in the glipizide group continued to show no meaningful change in mean SBP [week 104, −3.00 vs 0.89mmHg, respectively; week 208, −3.69 vs −0.02mmHg, respectively; difference, −3.67mmHg (95% CI −5.92, −1.41); Figure1C].